Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
Phase 3
Not yet recruiting
- Conditions
- Platinum-Resistant Primary Peritoneal CarcinomaPlatinum Resistant High Grade Epithelial Ovarian CancerPlatinum Resistant High Grade Serous Ovarian Cancer
- Interventions
- Drug: Paclitaxel Lipid SuspensionDrug: Conventional paclitaxel or Taxol
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 166
- Registration Number
- NCT06867562
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer, MCRPC
- Interventions
- Drug: 50 mg cabazitaxelDrug: 100 mg cabazitaxelDrug: 200 mg cabazitaxel
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06890832
Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment
Phase 2
Not yet recruiting
- Conditions
- Ulcerative Colitis (UC)Ulcerative Colitis, Active Moderate
- Interventions
- Drug: Tacrolimus Lipid Suspension for enemaDrug: Identical Tacrolimus-free Lipid Suspension for Enema
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06867042
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Phase 3
Active, not recruiting
- Conditions
- Bipolar 1 Disorder
- Interventions
- Drug: Endoxifen enteric-coated tablet (8 mg)Drug: Placebo Tablets
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 490
- Registration Number
- NCT06608641
- Locations
- 🇺🇸
Synexus, Cerritos, California, United States
🇺🇸NRC Research Institute, Orange, California, United States
🇺🇸Innovative Clinical Research, Inc., Miami Lakes, Florida, United States
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04315792
- Locations
- 🇺🇸
16420 NW 59 Avenue, Miami, Florida, United States
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Phase 3
Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 657
- Registration Number
- NCT03671044
- Locations
- 🇺🇸
Columbus Regional Research Institute, LLC, Columbus, Georgia, United States
🇺🇸Cox Medical Center, Springfield, Missouri, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath